CareTrust REIT (CTRE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
The annual meeting is scheduled for April 29, 2026, with proposals to elect six directors, approve executive compensation on an advisory basis, and ratify Deloitte as the independent auditor for 2026.
Only stockholders of record as of March 5, 2026, are entitled to vote, with multiple voting methods available including internet, mail, telephone, or in-person.
The company experienced significant growth in 2025, including a major UK acquisition, record capital deployment, and strong financial performance, with a 17% increase in normalized funds from operations per share and a 77% rise in market capitalization.
Voting matters and shareholder proposals
Proposals include electing six directors, advisory approval of executive compensation, and ratification of Deloitte as auditor.
Shareholders can submit proposals or director nominations for the 2027 meeting by specified deadlines and procedures.
The board recommends voting FOR all proposals.
Board of directors and corporate governance
The board consists of six directors, with three women and one African American member; four are independent under NYSE rules.
Board committees include audit, compensation, nominating and corporate governance, and sustainability/corporate responsibility, each with defined charters and responsibilities.
The board separates the roles of CEO and Chair, with regular self-evaluations and succession planning.
Directors and executives are subject to stock ownership guidelines and a code of business conduct and ethics.
Latest events from CareTrust REIT
- Q1 2025 delivered record earnings, a dividend hike, and a transformative UK acquisition.CTRE
Q1 20259 Jul 2026 - Rapid U.K. expansion, robust pipeline, and SHOP platform buildout drive future growth.CTRE
BofA Securities 2025 Global Real Estate Conference8 Jul 2026 - Q3 2024 net income surged to $33.4M, with record investments and a robust growth pipeline.CTRE
Q3 20248 Jul 2026 - Record 2025 growth and strong 2026 outlook with double-digit FFO and FAD gains projected.CTRE
Q4 20258 Jul 2026 - Q1 2026 delivered 48% revenue growth, double-digit FFO gains, and a raised full-year outlook.CTRE
Q1 20268 May 2026 - Record capital deployment and performance-driven executive pay defined 2025.CTRE
Proxy filing24 Mar 2026 - Definitive proxy statement outlines annual meeting proposals and confirms board oversight.CTRE
Proxy Filing13 Mar 2026 - Double-digit FFO growth, robust investments, and industry-leading returns drive shareholder value.CTRE
Investor presentation2 Mar 2026 - Q2 2024 saw record investments, robust growth, and historic low leverage with strong liquidity.CTRE
Q2 20242 Feb 2026